Aprea Therapeutics, Inc. (APRE) – What Are Brokerages Saying About This Stock?

Aprea Therapeutics, Inc. (NASDAQ:APRE) has been given an average recommendation of “Moderate Buy” by the six research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $2.80.

Several research firms have recently weighed in on APRE. Wedbush decreased their price objective on Aprea Therapeutics to $3.00 and set an “outperform” rating for the company in a report on Thursday, August 13th. LADENBURG THALM/SH SH initiated coverage on shares of Aprea Therapeutics in a report on Wednesday. They issued a “buy” rating and a $2.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Friday, July 17th.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Aprea Therapeutics stock. AIGH Capital Management LLC lifted its holdings in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) by 174.1% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,015,541 shares of the company’s stock after buying an additional 645,000 shares during the period. AIGH Capital Management LLC owned approximately 8.47% of Aprea Therapeutics worth $775,000 at the end of the most recent quarter. 34.19% of the stock is owned by institutional investors.

Aprea Therapeutics Stock Up 0.7%

APRE traded up $0.00 on Wednesday, reaching $0.60. The company had a trading volume of 14,425 shares, compared to its average volume of 878,766. Aprea Therapeutics has a 1 year low of $0.55 and a 1 year high of $1.69. The stock has a market capitalization of $7.60 million, a PE ratio of -0.56 and a beta of 1.66. The stock has a 50-day moving average price of $0.73 and a 200-day moving average price of $0.77.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.11. As a group, analysts expect that Aprea Therapeutics will post -0.34 earnings per share for the current fiscal year.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc (NASDAQ: APRE) is a clinical-stage biopharmaceutical company developing targeted therapies for cancer. Its research focuses on treatments designed to exploit weaknesses in tumor cells, with an emphasis on DNA damage response and cell-cycle regulation.

The company’s lead investigational program is ATRN-119, an oral, selective inhibitor of ataxia telangiectasia and Rad3-related protein, or ATR. ATRN-119 is being evaluated in early-stage clinical studies for patients with advanced solid tumors.